Multicenter Study of Seliciclib (R-roscovitine) for Cushing Disease
NCT03774446
·
clinicaltrials.gov ↗
PHASE2
Phase
RECRUITING
Status
13
Enrollment
OTHER
Sponsor class
Conditions
Cushing Disease
Interventions
DRUG:
Seliciclib
Sponsor
Cedars-Sinai Medical Center